Skip to main
RCEL

RCEL Stock Forecast & Price Target

RCEL Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

AVITA Medical demonstrated a positive financial trajectory, with full year 2025 revenue increasing to approximately $71.6 million, marking an 11% growth over the previous year and aligning with the company's revised guidance. The company exhibited an improvement in net cash use, reducing it sequentially from $6.2 million to approximately $5.1 million, indicating enhanced financial management. Additionally, management's guidance for 2026 revenue between $80 million and $85 million points to a potential resurgence in commercial momentum, driven by deeper market penetration and integration of its product offerings.

Bears say

Avita Medical's financial outlook is concerning due to a revision in revenue expectations, leading to a lowered valuation target from $14.00 to $10.00. The company reported a net loss of $11.6 million, maintaining a per-share loss of $0.38, which is slightly improved from $0.44 per share in the previous year, but still highlights ongoing challenges. Additionally, the focus on a single product, the RECELL system, and limited international marketing efforts raise further concerns about long-term growth potential and sustainability.

RCEL has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AVITA Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AVITA Medical Inc (RCEL) Forecast

Analysts have given RCEL a Buy based on their latest research and market trends.

According to 3 analysts, RCEL has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AVITA Medical Inc (RCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.